3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Liposarcoma
1
Leiomyosarcoma
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Interventions
Gemcitabine
13
Doxorubicin
8
Docetaxel
7
Trabectedin
5
pazopanib
4
Nivolumab
4
Temozolomide
3
Specimen Handling
3
Sorafenib
3
rucaparib
2
pembrolizumab
2
liposomal doxorubicin
2
durvalumab
2
brostallicin
2
Sunitinib
2
Radiotherapy
2
Radiation Dose Hypofractionation
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ifosfamide
2
Dacarbazine
2
Bevacizumab
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
talimogene laherparepvec
1
sotigalimab
1
soblidotin
1
saracatinib
1
rubitecan
1
romidepsin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leiomyosarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts